blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2937349

EP2937349 - FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.11.2017
Database last updated on 28.09.2024
FormerThe patent has been granted
Status updated on  25.11.2016
FormerGrant of patent is intended
Status updated on  18.11.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 / US
[2015/44]
Inventor(s)01 / Chen, Xiaoqi
970 Blair Court
Palo Alto, CA California 94303 / US
02 / Dai, Kang
619 Santa Fe Avenue
Albany, CA California 94706 / US
03 / Duquette, Jason A.
460 Bayview Avenue
Millbrae, CA California 94030 / US
04 / Gribble, Michael W., Jr.
949 Capp Street, Apt 22
San Francisco, CA California 94110 / US
05 / Huard, Justin N.
8031 28th Ave NW
Seattle, WA Washington 98117 / US
06 / Keegan, Kathleen S.
8264 NE Carmella Lane
Bainbridge Island, WA Washington 98110 / US
07 / LI, Zhihong
467 Anita Drive
Millbrae, CA California 94030 / US
08 / Lively, Sarah E.
1536 Eaton Avenue
San Carlos, CA California 94070 / US
09 / McGee, Lawrence R.
39 Big Sur Way
Pacifica, CA California 94044 / US
10 / Ragains, Mark L.
4129 S. Hulen Street, Apt. 822
Fort Worth, TX Texas 76109 / US
11 / Wang, Xianghong
4915 Shelton Street
Dublin, CA California 94568 / US
12 / Weidner, Margaret F.
15726 160th Ave NE
Woodinville, WA Washington 98072 / US
13 / Zhang, Jian
290 Pelican Court
Foster City, CA California 94404 / US
 [2015/44]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2015/44]
Application number, filing date15161337.921.03.2012
[2015/44]
Priority number, dateUS201161466841P23.03.2011         Original published format: US 201161466841 P
[2015/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2937349
Date:28.10.2015
Language:EN
[2015/44]
Type: B1 Patent specification 
No.:EP2937349
Date:28.12.2016
Language:EN
[2016/52]
Search report(s)(Supplementary) European search report - dispatched on:EP24.07.2015
ClassificationIPC:C07D471/14, C07D519/00, A61K31/519, A61P35/00, A61P35/02
[2015/44]
CPC:
C07D519/00 (EP,CN,US); C07D471/14 (EP,KR,US); A61K31/519 (KR);
A61P35/00 (EP); A61P35/02 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/22]
Former [2015/44]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:FUSIONIERTE TRICYCLISCHE DUALE INHIBITOREN VON CDK 4/6 UND FLT3[2015/44]
English:FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3[2015/44]
French:DOUBLES INHIBITEURS TRICYCLIQUES FUSIONNÉS DE CDK 4/6 ET FLT3[2015/44]
Examination procedure22.04.2016Examination requested  [2016/22]
28.04.2016Amendment by applicant (claims and/or description)
26.07.2016Communication of intention to grant the patent
14.11.2016Fee for grant paid
14.11.2016Fee for publishing/printing paid
14.11.2016Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP12711738.0  / EP2688887
Opposition(s)29.09.2017No opposition filed within time limit [2017/49]
Fees paidRenewal fee
27.03.2015Renewal fee patent year 03
27.03.2015Renewal fee patent year 04
10.03.2016Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.03.2012
AL28.12.2016
CY28.12.2016
CZ28.12.2016
EE28.12.2016
HR28.12.2016
LT28.12.2016
LV28.12.2016
MC28.12.2016
MK28.12.2016
PL28.12.2016
RO28.12.2016
RS28.12.2016
SI28.12.2016
SK28.12.2016
SM28.12.2016
LU21.03.2017
MT21.03.2017
BG28.03.2017
GR29.03.2017
IS28.04.2017
[2020/34]
Former [2019/52]HU21.03.2012
CY28.12.2016
CZ28.12.2016
EE28.12.2016
HR28.12.2016
LT28.12.2016
LV28.12.2016
MC28.12.2016
MK28.12.2016
PL28.12.2016
RO28.12.2016
RS28.12.2016
SI28.12.2016
SK28.12.2016
SM28.12.2016
LU21.03.2017
MT21.03.2017
BG28.03.2017
GR29.03.2017
IS28.04.2017
Former [2019/47]HU21.03.2012
CY28.12.2016
CZ28.12.2016
EE28.12.2016
HR28.12.2016
LT28.12.2016
LV28.12.2016
MC28.12.2016
PL28.12.2016
RO28.12.2016
RS28.12.2016
SI28.12.2016
SK28.12.2016
SM28.12.2016
LU21.03.2017
MT21.03.2017
BG28.03.2017
GR29.03.2017
IS28.04.2017
Former [2019/31]HU21.03.2012
CZ28.12.2016
EE28.12.2016
HR28.12.2016
LT28.12.2016
LV28.12.2016
MC28.12.2016
PL28.12.2016
RO28.12.2016
RS28.12.2016
SI28.12.2016
SK28.12.2016
SM28.12.2016
LU21.03.2017
MT21.03.2017
BG28.03.2017
GR29.03.2017
IS28.04.2017
Former [2018/43]CZ28.12.2016
EE28.12.2016
HR28.12.2016
LT28.12.2016
LV28.12.2016
MC28.12.2016
PL28.12.2016
RO28.12.2016
RS28.12.2016
SI28.12.2016
SK28.12.2016
SM28.12.2016
LU21.03.2017
MT21.03.2017
BG28.03.2017
GR29.03.2017
IS28.04.2017
Former [2018/14]CZ28.12.2016
EE28.12.2016
HR28.12.2016
LT28.12.2016
LV28.12.2016
MC28.12.2016
PL28.12.2016
RO28.12.2016
RS28.12.2016
SI28.12.2016
SK28.12.2016
SM28.12.2016
LU21.03.2017
BG28.03.2017
GR29.03.2017
IS28.04.2017
Former [2018/10]CZ28.12.2016
EE28.12.2016
HR28.12.2016
LT28.12.2016
LV28.12.2016
MC28.12.2016
PL28.12.2016
RO28.12.2016
RS28.12.2016
SK28.12.2016
SM28.12.2016
LU21.03.2017
BG28.03.2017
GR29.03.2017
IS28.04.2017
Former [2018/01]CZ28.12.2016
EE28.12.2016
HR28.12.2016
LT28.12.2016
LV28.12.2016
MC28.12.2016
PL28.12.2016
RO28.12.2016
RS28.12.2016
SK28.12.2016
SM28.12.2016
BG28.03.2017
GR29.03.2017
IS28.04.2017
Former [2017/42]CZ28.12.2016
EE28.12.2016
HR28.12.2016
LT28.12.2016
LV28.12.2016
PL28.12.2016
RO28.12.2016
RS28.12.2016
SK28.12.2016
SM28.12.2016
BG28.03.2017
GR29.03.2017
IS28.04.2017
Former [2017/34]CZ28.12.2016
HR28.12.2016
LT28.12.2016
LV28.12.2016
RS28.12.2016
GR29.03.2017
Former [2017/28]HR28.12.2016
LT28.12.2016
LV28.12.2016
RS28.12.2016
GR29.03.2017
Former [2017/12]LV28.12.2016
Documents cited:Search[AD]WO2009085185  (AMGEN INC [US], et al) [AD] 1-14 * page 4; example 1; claims 1,4,7,44 *;
 [AD]WO2009126584  (AMGEN INC [US], et al) [AD] 1-14 * claims 1,36 *
by applicantWO2009085185
 WO2009126584
 WO2007087276
 US6846630
 US4256108
 US4160452
 US4265874
 US6258812
 US2003105091
 WO0137820
 US6235764
 WO0132651
 US6630500
 US6515004
 US6713485
 US5521184
 US5770599
 US5747498
 WO02068406
 WO02066470
 WO02055501
 WO2004005279
 WO2004007481
 WO2004007458
 WO2004009784
 WO02059110
 WO9945009
 WO0059509
 WO9961422
 US5990141
 WO0012089
 WO0002871
 US2003162712
 US6413932
 US6727225
 US2002042368
 US5981245
 US5728813
 US5969110
 US6596852
 US6232447
 US6057124
 US5712291
 US5792783
 EP0970070
 JPH02233610
 EP0407122
 EP1813606
    - MORGAN, D. 0., ANNU. REV. CELL. DEV. BIOL., (1997), vol. 13, pages 261 - 291
    - DE CARCER, G. ET AL., CURR. MED. CHEM., (2007), vol. 14, pages 969 - 85
    - MALUMBRES, M. ET AL., NATURE REV. CANCER, (2001), vol. 1, pages 222 - 231
    - KAMB, A., CURR. TOP. MICROBIOLO. IMMUNOL., (1998), vol. 227, pages 139 - 148
    - CHANG, M. W. ET AL., J. CLIN. INVEST., (1995), vol. 96, page 2260
    - YANG, Z-Y. ET AL., PROC. NATL. ACAD. SCI. (USA, (1996), vol. 93, page 9905
    - BROOKS, E. E. ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 29207 - 29211
    - BUKANOV, N. O. ET AL., NATURE, (2006), vol. 4444, pages 949 - 952
    - SCHANG, L. M. ET AL., J. VIROL., (1998), vol. 72, page 5626
    - TANIGUCHI, K. ET AL., NAT. MED., (1999), vol. 5, pages 760 - 767
    - CHEN ET AL., J. NATL. CANCER INSTITUTE, (2000), vol. 92, pages 1999 - 2008
    - SCHMIDT, M, ONCOGENE, (2001), vol. 20, pages 6164 - 71
    - SATYANARAYANA, A. ET AL., ONCOGENE, (2009), vol. 28, pages 2925 - 39
    - MALUMBRES, M ET AL., CELL, (2004), vol. 118, pages 493 - 504
    - MALUMBRES, M ET AL., NATURE REV. CANCER, (2001), vol. 1, pages 222 - 31
    - YU, Q. ET AL., CANCER CELL, (2006), vol. 9, pages 3 - 32
    - PUYOL, M., CANCER CELL, (2010), vol. 18, pages 63 - 73
    - NAOFUMI, M. ET AL., LEUKEMIA RES., (2005), vol. 29, pages 557 - 64
    - DREXLER, H. G., LEUKEMIA, (1998), vol. 12, pages 845 - 59
    - HERMAN, J. G. ET AL., CANCER RES., (1997), vol. 57, pages 837 - 41
    - SCHOLL C. ET AL., SEMIN. ONCOL., (2008), vol. 35, pages 336 - 45
    - MESHINCHI S. ET AL., CLIN. CANCER RES., (2009), vol. 15, pages 4263 - 9
    - MACKAREHTSCHIAN K ET AL., IMMUNITY, (1995), vol. 3, pages 147 - 61
    - YAMAMOTO ET AL., BLOOD, (2001), vol. 97, no. 8, pages 2434 - 2439
    - JIANG, J. ET AL., BLOOD, (2004), vol. 104, no. 6, pages 1855 - 1858
    - KINDLER ET AL., BLOOD, (2005), vol. 105, no. 1, pages 335 - 340
    - REINDEL ET AL., BLOOD, (2006), vol. 107, no. 9, pages 3700 - 3707
    - KELLY ET AL., BLOOD, (2002), vol. 99, pages 310 - 318
    - WEISBERG, E. ET AL., ONCOGENE, (2010), vol. 29, pages 5120 - 34
    - CHU, S. H ET AL., DRUG RESIST. UPDATE, (2009), vol. 12, pages 8 - 16
    - HEIDEL, F. ET AL., BLOOD, (2006), vol. 107, pages 293 - 300
    - PRATZ, K. W. ET AL., BLOOD, (2009), vol. 139, pages 3938 - 46
    - TAM, W. F. ET AL., BEST PRACT. RES. CLIN. HAEMATOL., (2008), vol. 21, pages 13 - 20
    - WILEN, S. H. ET AL., TETRAHEDRON, (1997), vol. 33, page 2725
    - WILEN, S. H., Tables of Resolving Agents and Optical Resolutions, UNIV. OF NOTRE DAME PRESS, (1972), page 268
    - MATSUNO ET AL., "p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia", LEUKEMIA RES., (2005), vol. 29, no. 5, doi:doi:10.1016/j.leukres.2004.11.003, pages 557 - 564, XP004774320

DOI:   http://dx.doi.org/10.1016/j.leukres.2004.11.003
    - DE JONGE ET AL., "AML at older age: age related gene expression profiles reveal a paradoxical down-regulation of P16INK4A mRNA with prognostic significance", BLOOD, (2012), vol. 114, no. 14, pages 2869 - 2877
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.